CN103842359B - N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 - Google Patents

N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 Download PDF

Info

Publication number: CN103842359B
Authority: CN; China
Prior art keywords: methyl; phenyl; thiazol; acetamide; aminosulfonyl
Prior art date: 2011-09-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201280046744.6A

Other languages

English (en)

Chinese (zh)

Other versions

CN103842359A (zh

Inventor

W·施瓦布

A·比克曼

K·弗格特利

D·哈格

A·伦德

A·格瓦嫩博格

B·凯尔

J·雷泽

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aike 316 Co ltd

Original Assignee

Aicuris GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-26

Filing date

2012-09-26

Publication date

2016-05-25

2012-09-26 Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG

2012-09-26 Priority to CN201511005819.8A priority Critical patent/CN105541829A/zh

2014-06-04 Publication of CN103842359A publication Critical patent/CN103842359A/zh

2016-05-25 Application granted granted Critical

2016-05-25 Publication of CN103842359B publication Critical patent/CN103842359B/zh

Status Active legal-status Critical Current

2032-09-26 Anticipated expiration legal-status Critical

Links

0 **CC[*+]C1N=*C=CC1 Chemical compound **CC[*+]C1N=*C=CC1 0.000 description 5
BKVXQXDDUYHLEG-UHFFFAOYSA-N Cc(nc(N(C)C(Cc(cc1)ccc1-c1ccccn1)=O)[s]1)c1S(N)(=C)=O Chemical compound Cc(nc(N(C)C(Cc(cc1)ccc1-c1ccccn1)=O)[s]1)c1S(N)(=C)=O BKVXQXDDUYHLEG-UHFFFAOYSA-N 0.000 description 1
KPAUORDXNFURBA-UHFFFAOYSA-N OC(Cc(cc1)ccc1-c1ccccn1)=O Chemical compound OC(Cc(cc1)ccc1-c1ccccn1)=O KPAUORDXNFURBA-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Thiazole And Isothizaole Compounds (AREA)

CN201280046744.6A 2011-09-26 2012-09-26 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 Active CN103842359B (zh)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CN201511005819.8A CN105541829A (zh)	2011-09-26	2012-09-26	N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11007823A EP2573086A1 (en)	2011-09-26	2011-09-26	N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP11007823.5		2011-09-26
PCT/EP2012/068938 WO2013045479A1 (en)	2011-09-26	2012-09-26	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201511005819.8A Division CN105541829A (zh)	2011-09-26	2012-09-26	N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物

Publications (2)

Publication Number	Publication Date
CN103842359A CN103842359A (zh)	2014-06-04
CN103842359B true CN103842359B (zh)	2016-05-25

Family

ID=46889067

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201280046744.6A Active CN103842359B (zh)	2011-09-26	2012-09-26	N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物
CN201511005819.8A Pending CN105541829A (zh)	2011-09-26	2012-09-26	N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN201511005819.8A Pending CN105541829A (zh)	2011-09-26	2012-09-26	N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物

Country Status (29)

Country	Link
US (1)	US9340535B2 (2)
EP (3)	EP2573086A1 (2)
JP (2)	JP6161614B2 (2)
KR (4)	KR20190104249A (2)
CN (2)	CN103842359B (2)
AR (3)	AR088043A1 (2)
AU (2)	AU2012314536B2 (2)
BR (1)	BR112014003245B1 (2)
CA (1)	CA2791142C (2)
CL (1)	CL2014000149A1 (2)
DK (2)	DK2598501T3 (2)
ES (2)	ES2462492T3 (2)
HK (1)	HK1220978A1 (2)
HR (1)	HRP20140351T1 (2)
IL (2)	IL230152A (2)
IN (1)	IN2014DN01993A (2)
JO (2)	JO3037B1 (2)
MX (2)	MX338736B (2)
MY (2)	MY185063A (2)
PE (1)	PE20141148A1 (2)
PH (2)	PH12014500567A1 (2)
PL (2)	PL2602258T3 (2)
PT (1)	PT2598501E (2)
RU (2)	RU2669388C1 (2)
SG (1)	SG10201407430TA (2)
TW (2)	TWI532739B (2)
UA (2)	UA115317C2 (2)
WO (1)	WO2013045479A1 (2)
ZA (2)	ZA201401773B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2573086A1 (en) *	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en)	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
JP6918823B2 (ja) *	2016-04-06	2021-08-11	イノベーティブモレキュールズゲーエムベーハーＩｎｎｏｖａｔｉｖｅＭｏｌｅｃｕｌｅｓＧｍｂｈ	抗ウイルス剤として有用なアミノチアゾール誘導体
AR110250A1 (es) *	2016-11-28	2019-03-13	Aicuris Anti Infective Cures Gmbh	Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
AR110251A1 (es)	2016-11-28	2019-03-13	Aicuris Anti Infective Cures Gmbh	Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma
LT3544976T (lt) *	2016-11-28	2021-08-10	Aicuris Gmbh & Co. Kg	N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
KR102335327B1 (ko)	2017-04-28	2021-12-03	현대자동차 주식회사	수냉식 이지알 쿨러
PT3644958T (pt)	2017-06-28	2021-11-08	Aicuris Gmbh & Co Kg	Dispositivos aplicáveis intravaginalmente que compreendem compostos antivirais
WO2019068817A1 (en)	2017-10-05	2019-04-11	Innovative Molecules Gmbh	SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
JP7150368B2 (ja) *	2018-07-06	2022-10-11	フェーノ・セラピューティクス・カンパニー・リミテッド	チアゾール系化合物の結晶形およびその応用
AU2019345067A1 (en) *	2018-09-19	2021-04-08	Modernatx, Inc.	High-purity peg lipids and uses thereof
TW202038947A (zh)	2018-11-28	2020-11-01	德商創新分子有限責任公司	在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CA3168721A1 (en) *	2020-03-26	2021-09-30	Jessica Redmer	Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
WO2024047507A1 (en)	2022-08-29	2024-03-07	Assembly Biosciences, Inc.	A novel crystalline form of pritelivir
JP2025527942A (ja)	2022-08-29	2025-08-25	アセンブリー・バイオサイエンシーズ・インコーポレイテッド	新規な結晶形態
IL319024A (en)	2022-08-29	2025-04-01	Assembly Biosciences Inc	Pharmaceutical preparations for the herpes virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1235890C (zh) *	1999-12-23	2006-01-11	拜尔公司	噻唑基酰胺衍生物
WO2006103011A1 (de) *	2005-03-30	2006-10-05	Aicuris Gmbh & Co. Kg	Pharmazeutische zubereitung von n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10129716A1 (de) *	2001-06-22	2003-01-02	Bayer Ag	Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) *	2001-06-22	2003-01-02	Bayer Ag	Topische Anwendung von Thiazolylamiden
DE10129717A1 (de) *	2001-06-22	2003-01-02	Bayer Ag	Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) *	2001-06-28	2003-01-16	Bayer Ag	Sekundäre Sulfonamide
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
JP2007314516A (ja) *	2006-04-25	2007-12-06	Daiichi Sankyo Co Ltd	２以上の置換基を有するベンゼン化合物を含有する医薬
BRPI0712332A2 (pt) *	2006-06-09	2012-12-18	Icos Corp	composto e derivados farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
AR070127A1 (es) *	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) *	2009-03-02	2013-12-10	Айерем Элелси	N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573086A1 (en) *	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) *	2011-09-26	2013-03-27	AiCuris GmbH & Co. KG	N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range

2011
- 2011-09-26 EP EP11007823A patent/EP2573086A1/en not_active Withdrawn
2012
- 2012-09-21 TW TW101134784A patent/TWI532739B/zh active
- 2012-09-21 TW TW105109173A patent/TWI567070B/zh active
- 2012-09-23 JO JOP/2012/0276A patent/JO3037B1/ar active
- 2012-09-26 MX MX2014003389A patent/MX338736B/es active IP Right Grant
- 2012-09-26 PT PT127623007T patent/PT2598501E/pt unknown
- 2012-09-26 CN CN201280046744.6A patent/CN103842359B/zh active Active
- 2012-09-26 BR BR112014003245-9A patent/BR112014003245B1/pt active IP Right Grant
- 2012-09-26 ES ES12762300.7T patent/ES2462492T3/es active Active
- 2012-09-26 PH PH1/2014/500567A patent/PH12014500567A1/en unknown
- 2012-09-26 JP JP2014532361A patent/JP6161614B2/ja active Active
- 2012-09-26 DK DK12762300.7T patent/DK2598501T3/da active
- 2012-09-26 AU AU2012314536A patent/AU2012314536B2/en active Active
- 2012-09-26 KR KR1020197025387A patent/KR20190104249A/ko not_active Ceased
- 2012-09-26 ES ES13157396.6T patent/ES2466221T3/es active Active
- 2012-09-26 DK DK13157396.6T patent/DK2602258T3/da active
- 2012-09-26 CA CA2791142A patent/CA2791142C/en active Active
- 2012-09-26 WO PCT/EP2012/068938 patent/WO2013045479A1/en not_active Ceased
- 2012-09-26 HR HRP20140351AT patent/HRP20140351T1/hr unknown
- 2012-09-26 AR ARP120103551A patent/AR088043A1/es not_active Application Discontinuation
- 2012-09-26 IN IN1993DEN2014 patent/IN2014DN01993A/en unknown
- 2012-09-26 KR KR1020147004026A patent/KR101768295B1/ko active Active
- 2012-09-26 EP EP12762300.7A patent/EP2598501B1/en active Active
- 2012-09-26 RU RU2017114501A patent/RU2669388C1/ru active
- 2012-09-26 US US14/347,287 patent/US9340535B2/en active Active
- 2012-09-26 MY MYPI2014000656A patent/MY185063A/en unknown
- 2012-09-26 CN CN201511005819.8A patent/CN105541829A/zh active Pending
- 2012-09-26 MX MX2015016192A patent/MX371088B/es unknown
- 2012-09-26 SG SG10201407430TA patent/SG10201407430TA/en unknown
- 2012-09-26 PE PE2014000390A patent/PE20141148A1/es active IP Right Grant
- 2012-09-26 EP EP13157396.6A patent/EP2602258B8/en active Active
- 2012-09-26 UA UAA201404411A patent/UA115317C2/uk unknown
- 2012-09-26 KR KR1020187021891A patent/KR20180088530A/ko not_active Ceased
- 2012-09-26 PL PL13157396T patent/PL2602258T3/pl unknown
- 2012-09-26 KR KR1020177012548A patent/KR20170055565A/ko not_active Ceased
- 2012-09-26 PL PL12762300T patent/PL2598501T3/pl unknown
- 2012-09-26 UA UAA201704493A patent/UA119574C2/uk unknown
- 2012-09-26 MY MYPI2017702805A patent/MY190878A/en unknown
- 2012-09-26 RU RU2014107430A patent/RU2620604C2/ru active
2013
- 2013-12-24 IL IL230152A patent/IL230152A/en active IP Right Grant
2014
- 2014-01-20 CL CL2014000149A patent/CL2014000149A1/es unknown
- 2014-03-11 ZA ZA2014/01773A patent/ZA201401773B/en unknown
- 2014-09-01 IL IL234405A patent/IL234405A/en active IP Right Grant
- 2014-09-02 HK HK16109165.2A patent/HK1220978A1/zh unknown
- 2014-11-27 ZA ZA2014/08734A patent/ZA201408734B/en unknown
2015
- 2015-11-24 AU AU2015260762A patent/AU2015260762B2/en active Active
- 2015-12-16 PH PH12015502801A patent/PH12015502801A1/en unknown
2016
- 2016-06-07 JO JOP/2016/0114A patent/JO3734B1/ar active
- 2016-12-22 JP JP2016249351A patent/JP6353022B2/ja active Active
2019
- 2019-09-13 AR ARP190102595A patent/AR116394A2/es not_active Application Discontinuation
2020
- 2020-10-23 AR ARP200102938A patent/AR120291A2/es unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1235890C (zh) *	1999-12-23	2006-01-11	拜尔公司	噻唑基酰胺衍生物
WO2006103011A1 (de) *	2005-03-30	2006-10-05	Aicuris Gmbh & Co. Kg	Pharmazeutische zubereitung von n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293;Ulrich A. K. Betz，等;《Antimicrobial agents and chemotherapy》;20020630;第46卷(第6期);第1766-1772页 *

Also Published As

Publication number	Publication date
NZ621615A (en)	2016-04-29
JP2017114859A (ja)	2017-06-29
IN2014DN01993A (2)	2015-05-15
IL230152A (en)	2015-04-30
JO3037B1 (ar)	2016-09-05
CA2791142C (en)	2017-08-01
BR112014003245A2 (pt)	2017-03-01
PH12014500567A1 (en)	2014-04-14
HK1220978A1 (zh)	2017-05-19
KR20180088530A (ko)	2018-08-03
AR116394A2 (es)	2021-05-05
CN105541829A (zh)	2016-05-04
RU2669388C1 (ru)	2018-10-11
KR20190104249A (ko)	2019-09-06
ZA201408734B (en)	2016-08-31
RU2620604C2 (ru)	2017-05-29
WO2013045479A1 (en)	2013-04-04
BR112014003245B1 (pt)	2021-11-09
HRP20140351T1 (hr)	2014-07-04
DK2602258T3 (da)	2014-04-22
IL234405A (en)	2015-04-30
PH12015502801B1 (en)	2016-10-03
KR20140066704A (ko)	2014-06-02
SG10201407430TA (en)	2014-12-30
EP2598501A1 (en)	2013-06-05
KR20170055565A (ko)	2017-05-19
US9340535B2 (en)	2016-05-17
EP2602258B1 (en)	2014-03-19
CA2791142A1 (en)	2013-03-26
AU2015260762A1 (en)	2016-02-04
MY190878A (en)	2022-05-13
ES2466221T3 (es)	2014-06-09
JP6161614B2 (ja)	2017-07-12
PL2602258T3 (pl)	2014-08-29
AU2015260762B2 (en)	2016-06-09
EP2573086A1 (en)	2013-03-27
PH12015502801A1 (en)	2016-10-03
CN103842359A (zh)	2014-06-04
MX2014003389A (es)	2014-07-09
NZ718867A (en)	2016-05-27
AR120291A2 (es)	2022-02-09
AU2012314536A1 (en)	2014-02-06
MX338736B (es)	2016-04-29
EP2598501B1 (en)	2014-03-12
TW201317234A (zh)	2013-05-01
MY185063A (en)	2021-04-30
PE20141148A1 (es)	2014-09-15
DK2598501T3 (da)	2014-04-22
ES2466221T8 (es)	2016-09-13
TW201625603A (zh)	2016-07-16
ZA201401773B (en)	2015-12-23
UA119574C2 (uk)	2019-07-10
ES2462492T3 (es)	2014-05-23
PT2598501E (pt)	2014-06-25
EP2602258B8 (en)	2016-09-28
TWI532739B (zh)	2016-05-11
EP2602258A1 (en)	2013-06-12
CL2014000149A1 (es)	2014-09-05
AR088043A1 (es)	2014-05-07
KR101768295B1 (ko)	2017-08-14
TWI567070B (zh)	2017-01-21
MX371088B (es)	2020-01-16
US20140221433A1 (en)	2014-08-07
JO3734B1 (ar)	2021-01-31
PL2598501T3 (pl)	2014-08-29
JP6353022B2 (ja)	2018-07-04
JP2014528948A (ja)	2014-10-30
RU2014107430A (ru)	2015-11-10
AU2012314536B2 (en)	2016-01-14
UA115317C2 (uk)	2017-10-25

Legal Events

Date	Code	Title	Description
2014-06-04	C06	Publication
2014-06-04	PB01	Publication
2014-10-22	C10	Entry into substantive examination
2014-10-22	SE01	Entry into force of request for substantive examination
2014-11-28	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1196018 Country of ref document: HK
2016-05-25	C14	Grant of patent or utility model
2016-05-25	GR01	Patent grant
2017-09-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1196018 Country of ref document: HK
2024-08-23	TR01	Transfer of patent right	Effective date of registration: 20240806 Address after: Germany Patentee after: Aike 316 Co.,Ltd. Country or region after: Germany Address before: Wolpertal, Germany Patentee before: AICURIS GmbH & Co.KG Country or region before: Germany
2024-08-23	TR01	Transfer of patent right

Publication	Publication Date	Title
CN103842359B (zh)	2016-05-25	N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物
CN103842360B (zh)	2016-06-22	用于药物制剂的具有特定粒度分布范围和比表面积范围的n-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物
KR20070050967A (ko)	2007-05-16	4-[[(7ｒ)-8-사이클로펜틸-7-에틸-5,6,7,8-테트라하이드로-5-메틸-4-6-옥소-2-프테리디닐]아미노]-3-메톡시-ｎ-(1-메틸-4-피페리디닐)벤즈아미드의 수화물 및 다형체, 이들의제조방법, 및 약제로서의 이들의 용도
CA2939529C (en)	2018-07-03	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196018A (en)	2014-11-28	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196018B (en)	2017-09-22	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
NZ621615B2 (en)	2016-08-02	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
NZ718867B2 (en)	2016-08-30	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate